

1 **SARS-CoV-2 variants Omicron BA.4/5 and XBB.1.5 significantly escape T cell recognition**
2 **in solid organ transplant recipients vaccinated against the ancestral strain**

3
4 Torin Halvorson^{1,2,3}, Sabine Ivison^{2,3}, Qing Huang^{2,3}, Gale Ladua^{1,4}, Demitra M. Yotis⁵, Dhiraj
5 Mannar⁶, Sriram Subramaniam⁶, Victor H. Ferreira⁷, Deepali Kumar⁷, Sara Belga^{1,4,*}, and Megan
6 K. Levings^{2,3,8,*}, on behalf of the PREVenT study group

7
8 ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada

9 ²Department of Surgery, University of British Columbia, Vancouver, BC, Canada

10 ³BC Children's Hospital Research Institute, Vancouver, BC, Canada

11 ⁴Vancouver Coastal Health Research Institute, Vancouver BC, Canada

12 ⁵Canadian Donation and Transplantation Research Program, Edmonton, AB, Canada

13 ⁶Department of Biochemistry and Molecular Biology, University of British Columbia,
14 Vancouver, BC, Canada

15 ⁷Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada

16 ⁸School of Biomedical Engineering, University of British Columbia, Vancouver BC, Canada

17 *These authors contributed equally

18
19
20 Correspondence information: mlevings@bcchr.ca

21 Megan Levings: BC Children's Hospital Research Institute, 950 West 28th Ave, Vancouver BC,

22
23 Word count for the abstract: 248/250

24 Word count for the main text: 3875/4000

25 Number of tables: 2

26 Number of figures: 6

27 Number of references: 67

28

29 Keywords: vaccine, COVID-19, T cell, solid organ transplantation, activation-induced marker
30 assay

31

32

33

34

35

36 **AUTHORSHIP PAGE**

37

38 **Author Contributions**

39 **TH** research design, paper writing, performance of the research, data analysis, statistical analyses

40 **SI** research design, paper writing, data analysis

41 **QH** research design, performance of the research

42 **GL** performance of the research, data analysis

43 **DY** performance of the research, data analysis

44 **DM** research design, performance of the research, paper writing

45 **SS** research design, paper writing

46 **VHF** data analysis, research design

47 **DK** research design

48 **SB** research design, performance of the research

49 **MKL** research design, paper writing

50

51

52 **Disclosures:** D.K. has received consulting fees from Roche, GSK, Exevir and clinical trials
53 grants from GSK. S. B. has received consultant fees from AstraZeneca and GSK, honoraria from
54 Merck and research funding from Takeda. The remaining authors have no relevant conflicts to
55 disclose.

56

57 **Funding:**

58 This work was supported by a grant from Public Health Agency of Canada / COVID-19
59 Immunity Task Force (AWD-019932 PHACA 2021) and the Canadian Institutes of Health
60 Research (HUI-159423). MKL holds a salary award from the BC Children's Hospital Research
61 Institute and a Tier 1 Canada Research Chair in Engineered Immune Tolerance. This study was
62 coordinated by the Canadian Donation and Transplantation Research Program (CDTRP).

63

64

65

66

67

68

69 **Abbreviations**

70 AIM, activation-induced marker

71 BA.4/5, Omicron BA.4 and BA.5 variants

72 COVID-19, coronavirus disease of 2019

73 DMSO, dimethyl sulfoxide

74 ICS, intracellular cytokine staining

75 IQR, interquartile range

76 IFN- γ , interferon- γ

77 IL-2, interleukin-2

78 mRNA, messenger RNA

79 nAb, neutralizing antibody

80 PBMCs, peripheral blood mononuclear cells

81 RBD, receptor-binding domain

82 SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

83 SOTR, solid organ transplant recipient

84

85 **Abstract**

86 *Background*

87 Immune-suppressed solid organ transplant recipients (SOTRs) display impaired humoral
88 responses to COVID-19 vaccination, but T cell responses are incompletely understood. The
89 highly infectious SARS-CoV-2 variants Omicron BA.4/5 and XBB.1.5 escape neutralization by
90 antibodies induced by vaccination or infection with earlier strains, but T cell recognition of these
91 lineages in SOTRs is unclear.

92 *Methods*

93 We characterized Spike-specific T cell responses to ancestral SARS-CoV-2, Omicron BA.4/5 and
94 XBB.1.5 peptides in a prospective study of kidney, lung and liver transplant recipients (n = 42)
95 throughout a three- or four-dose ancestral Spike mRNA vaccination schedule. Using an
96 optimized activation-induced marker assay, we quantified circulating Spike-specific CD4+ and
97 CD8+ T cells based on antigen-stimulated expression of CD134, CD69, CD25, CD137 and/or
98 CD107a.

99 *Results*

100 Vaccination strongly induced SARS-CoV-2-specific T cells, including BA.4/5- and XBB.1.5-
101 reactive T cells, which remained detectable over time and further increased following a fourth
102 dose. However, responses to Omicron BA.4/5 and XBB.1.5 were significantly lower in
103 magnitude compared to ancestral strain responses. Antigen-specific CD4+ T cell frequencies
104 correlated with anti-receptor-binding domain (RBD) antibody titres, with post-second dose T cell
105 responses predicting subsequent antibody responses. Patients receiving prednisone, lung
106 transplant recipients and older adults displayed weaker responses.

107 *Conclusions*

108 Ancestral strain vaccination stimulates BA.4/5 and XBB.1.5-cross-reactive T cells in SOTRs, but
109 responses to these variants are diminished. Antigen-specific T cells can predict future antibody
110 responses and identify vaccine responses in seronegative individuals. Our data support
111 monitoring both humoral and cellular immunity in SOTRs to track effectiveness of COVID-19
112 vaccines against emerging variants.

113

114 Introduction

115 COVID-19 vaccines effectively reduce infections, hospitalizations and mortality from SARS-
116 CoV-2¹⁻³. However, immune-suppressed populations such as solid-organ transplant recipients
117 (SOTRs), who require lifelong immune-suppressive therapy to prevent allograft rejection, remain
118 at elevated risk from COVID-19 despite vaccination⁴. SOTRs display impaired humoral
119 immunity to COVID-19 vaccination, with decreased anti-Spike binding and neutralizing
120 antibody (nAb) responses compared to the general population⁵⁻⁸. However, a third or fourth
121 ‘booster’ dose significantly increases seropositivity and nAbs in SOTRs^{6,9,10}.

122 As SARS-CoV-2 continues to evolve, emerging variants, including Omicron lineages and their
123 derivatives, continue to challenge global COVID-19 immunity¹¹⁻¹⁵. The Omicron BA.4 and
124 BA.5 (henceforth BA.4/5) subvariants display over 40 Spike protein mutations and enhanced
125 affinity for the ACE2 receptor^{13,16}. More recently, recombinant BA.2-derived XBB lineages have
126 emerged, with XBB.1.5 the latest to dominate globally^{14,15,17,18}. These subvariants are highly
127 infectious and evade neutralization by vaccination- or infection-induced nAbs targeting the
128 ancestral strain¹⁶. Neutralization of XBB lineages is reduced more than 100-fold relative to
129 ancestral SARS-CoV-2, even after vaccination with BA.4/5 bivalent vaccines¹⁷⁻²⁰.

130 Cellular immunity to SARS-CoV-2 in SOTRs is less well understood. SARS-CoV-2-specific T
131 cell responses are widely recognized to be critical in mitigating severe COVID-19 disease²¹⁻²³,
132 with CD4+ and CD8+ responses correlating negatively with disease severity²⁴ and breakthrough
133 infection risk post-vaccination²⁵. Furthermore, memory T cells cross-recognize emerging
134 variants, including Omicron and the BA sublineages^{18,25-27}. However, SOTRs display poor
135 cellular responses to vaccination, with lower Spike-specific CD4+ and CD8+ T cell frequencies
136 compared to healthy controls two weeks and six months after two-dose vaccination^{25,28}.
137 Vaccination also induces comparatively weaker Spike-specific IFN- γ + and/or IL-2+ T cell
138 responses than natural infection in SOTRs^{29,30}.

139 While it is well-established that BA.4/5 and XBB.1.5 escape antibody neutralization, whether
140 vaccination against the ancestral strain induces T cell responses cross-recognizing these variants
141 is unclear in SOTRs. A recent study assessed T cell responses to a fourth mRNA vaccine dose by
142 intracellular cytokine staining (ICS) in a small cohort of SOTRs, finding that a fourth dose
143 significantly increased frequencies of IFN- γ +/IL-2+ BA.4/5-specific CD4+, but not CD8+, T
144 cells⁹. Only one study has directly compared ancestral SARS-CoV-2- and BA.4/5-specific T cell
145 responses in SOTRs, showing no differences in magnitude by ICS³¹. However, ICS does not
146 quantify the full diversity of antigen-specific T cells^{32,33}. Alternatively, activation-induced marker
147 (AIM) assays leverage T cell surface protein upregulation in response to antigen-specific
148 stimulation, broadly quantifying antigen-specific T cells independently of proliferation or
149 cytokine production³²⁻³⁵. Indeed, AIM assays are increasingly used to assess T cell responses to
150 SARS-CoV-2 infection and vaccination^{24,27,28,36}.

151 Here, we used the AIM method to characterize vaccine-induced SARS-CoV-2-specific T cells in
152 a prospective cohort of 42 liver, kidney and lung transplant recipients. Of specific interest was

153 whether vaccination against the SARS-CoV-2 ancestral strain would stimulate T cells with cross-
154 reactivity to Omicron BA.4/5 and/or XBB.1.5.

155 **Methods (see also Extended Methods)**

156

157 *Study Design and Enrollment*

158 The PREVenT-COVID study is a Canadian prospective study of vaccine immunogenicity in
159 SOTRs across seven tertiary care transplant centres^{9,37}. This study of cell-mediated immunity
160 was conducted at the University of British Columbia (UBC) with approval from the UBC
161 Research Ethics Board (H21-01269). Adult SOTRs provided informed consent and were enrolled
162 at first dose of an approved monovalent COVID-19 mRNA vaccine, BNT162b2 (Pfizer-
163 BioNTech,) or mRNA-1273 (Moderna), beginning January 2021. Whole blood was drawn from
164 participants within 2 weeks prior to the second dose, 3-6 weeks post-second dose, 6 months post-
165 first dose, 3-6 weeks post-third dose and one year post-first dose. One-year samples served as
166 post-fourth dose (3-6 weeks) samples in a subset of patients. PBMCs were collected from blood
167 samples and cryopreserved at -80°C. Participants were to inform the study team if they
168 developed COVID-19 for confirmation via PCR or rapid antigen test.

169

170 *Activation-Induced Marker Assays*

171 SARS-CoV-2 ancestral strain (PM-WCPV-S-1, JPT) and Omicron BA.4/5 (PM-SARS2-
172 SMUT10-1, JPT) overlapping peptide pools corresponding to the complete Spike proteins were
173 aliquoted in 30% DMSO and stored at -80°C. Cryopreserved PBMCs were thawed into 37°C
174 Immunocult XF (10981, STEMCELL) with 1% penicillin/streptomycin and 50 U/mL benzonase
175 (70664-3, Novagen). PBMCs were rested overnight at 37°C in Immunocult XF with 1%
176 penicillin/streptomycin and stimulated for 20 h at $4-5 \times 10^5$ cells per condition in 200 μ L with 1
177 μ g/mL SARS-CoV-2 ancestral strain or BA.4/5 Spike peptides, equimolar dimethyl sulfoxide
178 (DMSO, 0.12%), Fluzone® Quadrivalent influenza vaccine (2.5%) (Sanofi-Pasteur) or Cytostim
179 (0.05%) (130-092-172, Miltenyi). CD4 and CD107a staining antibodies were added during
180 stimulation, with surface staining for CD3, CD4, CD8, CD25, CD69, CD134, and CD137 after
181 stimulation. Data were acquired on an LSR Fortessa (BD) flow cytometer on high-throughput
182 sampler (HTS) mode. Antigen-specific CD4⁺ T cells were defined as CD134⁺/CD25⁺,
183 CD134⁺/CD69⁺ or CD137⁺/CD69⁺ while antigen-specific CD8⁺ T cells were defined as
184 CD107a⁺/CD69⁺, CD107a⁺/CD137⁺ or CD137⁺/CD69⁺, as previously described^{24,38-46}.

185

186 Whole protein stimulations were performed with protein isolates (**Extended Methods**) from
187 ancestral SARS-CoV-2 or XBB1.5 at 0.5 μ g/mL, equivolumetric PBS, 1 μ g/mL ancestral strain
188 peptides or 0.05% Cytostim for 44 h.

189

190 *Data Analysis*

191 Data were analyzed using FlowJo v10.8.1 and GraphPad Prism v10.0.0. Antigen-specific T cells
192 were quantified as the percentage of CD4⁺ or CD8⁺ T cells expressing each AIM marker, after
193 subtracting the frequency of AIM⁺ cells in the equivalent unstimulated condition. Net AIM
194 frequencies less than 0.005%, considered the limit of detection for the assay, were set to equal
195 0.005% to avoid negative or zero values. Samples with fewer than 10 000 total CD4⁺ or CD8⁺ T
196 cells were excluded. AIM responses were compared across timepoints using a mixed-effects
197 analysis (REML) on log₂-transformed data, assuming sphericity, with post-hoc Dunnett's

198 multiple comparisons test. Patients who received a fourth dose or contracted COVID-19 were
199 initially excluded to assess the duration of vaccine-induced T cell immunity.

200
201 Responses at one year were compared within (paired Wilcoxon tests) and between (Kruskal-
202 Wallis test with Dunn's multiple comparisons) control, post-fourth dose (within 3-6 weeks) and
203 hybrid (fourth dose and contracted COVID-19) groups. Post-third dose BA.4/5 and XBB.1.5
204 responses were compared to the ancestral strain by paired Wilcoxon tests. Post-third dose AIM
205 responses between groups defined by clinical parameters were compared using Mann-Whitney
206 and Kruskal-Wallis tests as appropriate. Semilogarithmic regression analysis modelled the
207 continuous effects of age and time since transplantation on post-third dose AIM responses.

208
209 Spearman's correlations assessed relationships between post-third dose T cell AIM responses
210 and published serum anti-RBD titres from the same individuals⁹. In patients with undetectable
211 anti-RBD antibodies post-second dose, log-log regression modelled the relationship between
212 post-second dose CD4+ AIM responses and post-third dose anti-RBD antibodies. Post-third dose
213 BA.4/5-specific AIM responses were compared between individuals with and without detectable
214 BA.4/5-neutralizing antibodies⁹ by paired t-tests on log₂-transformed AIM+ frequencies.

215 216 **Results**

217 *Study Population*

218 The study cohort consisted of 42 SOTRs with a median age of 58 (IQR 47-56), of which 22
219 (52%) were female and 20 (48%) were male (**Table 1, Figure S1**). Subjects were recipients of
220 kidney (n = 16), liver (n = 16) or lung (n = 10) transplants. Median time since transplantation
221 was 6.8 years (IQR 3.1-12.9). All subjects received at least two doses of monovalent Pfizer-
222 BioNTech BNT162b2 or Moderna mRNA-1273 COVID-19 vaccines. As one-year samples were
223 collected soon (3-6 weeks) after patients received a fourth dose, subjects were grouped as neither
224 having contracted COVID-19 nor received a fourth dose (controls, n = 6), post-fourth dose (n =
225 15), post-fourth dose and contracted COVID-19 ('hybrid', n = 7) or contracted COVID-19 only
226 (n = 4). At enrollment, all patients were receiving at least one immune-suppressive drug, with
227 tacrolimus (35/42, 83%) mycophenolate mofetil or mycophenolate sodium (27/42, 64%) and
228 prednisone (20/42, 48%) being the most frequent.

229 *COVID-19 vaccination induces significant and durable BA.4/5-specific T cell responses in solid- 230 organ transplant recipients*

231 We assessed T cell AIM responses following stimulation with SARS-CoV-2 ancestral strain or
232 BA.4/5 peptides throughout a 3-4 dose COVID-19 vaccination schedule (**Figure 1A**). Antigen-
233 specific CD4+ T cells (CD134+/CD25+, CD134+/CD69+ or CD137+/CD69+) and CD8+ T cells
234 (CD107a+/CD69+, CD107a+/CD137+ or CD137+/CD69+) were quantified (**Figure 1B, Figure
235 S2**). Ancestral- and BA.4/5-specific CD4+ AIM responses increased significantly after a second
236 dose (p <0.0001) but trended lower at six months (**Figure 1C**). A third dose induced significant
237 responses that remained elevated above pre-second dose levels at one year (p <0.0001). Similar
238 results were observed for CD8+ T cell responses, but with lower AIM+ frequencies and
239 substantial heterogeneity between donors (**Figure 1C**). However, post-third dose responses to
240 ancestral SARS-CoV-2 were significant for all CD8 AIM markers analyzed, and BA.4/5-specific

241 CD137+/CD69+ responses were significant at post-second dose, post-third dose and one-year
242 timepoints.

243 As a control, we measured CD4+ and CD8+ responses to an inactivated influenza vaccine
244 (Fluzone® Quadrivalent, Sanofi-Pasteur) at the same timepoints (**Figure S3A, B, C**). COVID-19
245 vaccination induced no changes in influenza-specific T cell responses, supporting the specificity
246 of our assays. Furthermore, cryopreserved replicate PBMC aliquots from two healthy controls
247 showed stable AIM responses over several months (**Figure S4**), demonstrating low technical
248 variation of the assay. For simplicity, we focused further analyses on CD134+/CD69+ CD4+ T
249 cell responses, and CD137+/CD69+ CD8+ T cell responses, as these AIMS are widely
250 used^{24,33,44,45,47-49} and showed the strongest trends across vaccination timepoints.

251 *A fourth monovalent ancestral vaccine dose boosts BA.4/5-specific T cell responses*

252 A subset of patients received a fourth dose 3-6 weeks prior to one-year sample collection, with
253 some additionally contracting COVID-19 (hereafter ‘hybrid’) (**Figure 2A**), allowing us to ask if
254 a 4th dose further increased BA.4/5-specific T cell immunity. Indeed, fourth dose recipients and
255 hybrid patients showed trending or significant increases above post-third dose levels in ancestral-
256 and BA.4/5-specific CD4+ responses (**Figure 2B**), with these increases being significantly
257 greater than observed in controls who received no fourth dose (**Figure 2C**). No significant
258 differences were identified between the fourth dose and hybrid groups.

259 *T cell responses to Omicron BA.4/5 are lower in magnitude than responses to the ancestral strain*

260 Having established that second and third doses of the monovalent ancestral vaccine induce
261 BA.4/5-responsive CD4+ and CD8+ T cells, we next compared the magnitude of post-third dose
262 BA.4/5-specific AIM responses with ancestral strain responses. Among CD4+ T cells, responses
263 to peptides from Omicron BA.4/5 were lower compared to ancestral SARS-CoV-2: median
264 frequencies of CD134+/CD25+ (1.67-fold lower, Wilcoxon signed-rank test $p < 0.0001$),
265 CD134+/CD69+ (1.38-fold lower, $p < 0.0001$), and CD137+/CD69+ (1.34-fold lower, $p =$
266 0.0022) were diminished (**Figure 3A**). Similar trends were observed among CD8+ T cells,
267 particularly when comparing CD137+/CD69+ frequencies (1.45-fold lower, $p = 0.0071$) (**Figure**
268 **3B**).

269 *Patients receiving prednisone, lung transplant recipients and older individuals display weaker T* 270 *cell responses*

271 We next sought to identify patient characteristics associated with weaker BA.4/5-specific AIM
272 responses, using post-third dose data for its large sample size and clinical relevance. Compared
273 to patients not receiving prednisone, patients on prednisone at baseline showed significantly
274 lower CD4+ (1.53-fold lower, Mann-Whitney U-test $p = 0.030$) and CD8+ (3.36-fold lower, $p =$
275 0.017) responses to BA.4/5, with similar trends for ancestral strain responses (**Figure 4A**). Since
276 all lung and no liver recipients were receiving prednisone at baseline, we also compared
277 responses by organ type (**Figure 4B**), showing trending or significantly lower BA.4/5-specific
278 CD4+ AIM responses in lung transplant recipients compared to liver (4.97-fold lower, $p =$
279 0.0017) and kidney (3.23-fold lower, $p = 0.0877$), with similar results for ancestral responses
280 (lung vs liver, 3.28-fold lower, $p = 0.0029$; lung vs kidney, 3.71-fold lower, $p = 0.0161$) (**Figure**
281 **4B**). CD8+ AIM responses followed similar trends but were non-significant.

282 Using semilogarithmic regression to model the effect of age on AIM responses, we identified
283 significant declines in AIM responses with age (**Figure 4C**). The regression line slope was
284 significantly different from zero for CD4+ ancestral- ($y = -0.0108x + 0.0100$, $p = 0.0390$) and
285 BA.4/5-specific responses ($y = -0.0127x + 0.0100$, $p = 0.0238$), with even stronger relationships
286 identified for CD8+ responses (ancestral, $y = -0.0194x + 0.3949$, $p = 0.0146$; BA.4/5, $y = -$
287 $0.0267x + 0.6728$, $p = 0.0059$). There were no significant differences in post-third dose AIM
288 responses between males and females (**Figure S5A**), or between patients vaccinated primarily
289 with Pfizer-BioNTech BNT162b2 compared to Moderna mRNA-1273 (**Figure S5B**).

290 *SARS-CoV-2-specific T cell responses correlate with circulating anti-Spike antibodies*

291 We investigated correlations between CD4+ T cell AIM responses and previously published anti-
292 RBD binding antibody titres measured in the same individuals at the same timepoints⁹.
293 CD134+/CD69+ CD4+ T cell AIM responses correlated strongly with antibody levels (**Figure**
294 **5A, Table 2**). At pre- and post-second dose timepoints, there were weak to moderate correlations
295 with antibody titres for CD4+ T cell responses to ancestral SARS-CoV-2 (pre-second dose
296 Spearman's $r = 0.2369$, $p = 0.2884$; post-second dose $r = 0.3064$, $p = 0.0514$) and BA.4/5 (pre-
297 second dose $r = 0.4066$, $p = 0.0604$; post-second dose $r = 0.3091$, $p = 0.0493$). However, the
298 strength and significance of these correlations increased over time, even without additional
299 vaccinations, and were further enhanced by a third dose, for both responses to the ancestral strain
300 (six months $r = 0.8028$, $p = 0.0082$; post-third dose $r = 0.6755$, $p < 0.0001$) and BA.4/5 (six
301 months $r = 0.6554$, $p = 0.0454$; post-third dose $r = 0.6411$, $p < 0.0001$). By contrast, antibody
302 correlations with CD8+ AIM responses did not follow a clear trend and were only significant for
303 post-third dose ancestral strain responses ($r = 0.3527$, $p = 0.0441$) (**Figure 5A, Table 2**).

304 As a substantial proportion of patients showed strong T cell responses but no detectable antibody
305 titres post-second dose, we assessed whether post-second dose CD4+ T cell responses could
306 predict subsequent post-third dose antibodies in these patients ($n = 19$). Log-log regression
307 analysis identified a strong positive relationship, with patients who demonstrated stronger T cell
308 responses to ancestral SARS-CoV-2 ($y = 1.313x + 3.359$, $p < 0.0001$) or BA.4/5 ($y = 1.371x +$
309 3.518 , $p < 0.0001$) subsequently showing stronger post-third dose antibody responses (**Figure**
310 **5B**). We also assessed the relationship of post-third dose T cell AIM responses with the presence
311 or absence of BA.4/5-specific nAbs in a subset of patients ($n = 18$). Although only four patients
312 developed nAbs post-third dose, there was a clear trend toward higher CD4+ and CD8 AIM+
313 frequencies in these patients (**Figure 5C**). This trend was less apparent after a fourth dose.

314 *Significant escape from T cell recognition by the novel variant XBB.1.5 in SOTRs*

315 We next asked whether three-dose ancestral COVID-19 vaccination induced T cells capable of
316 cross-recognizing the novel XBB.1.5 variant, using whole protein isolates in a subset of the
317 study cohort ($n = 10$) for which we had additional pre-second dose and post-third dose PBMC
318 samples. Although few XBB.1.5-specific T cells were observed prior to a second dose, three
319 COVID-19 vaccine doses significantly induced XBB.1.5-responsive CD4+ T cells (**Figure 6A**).
320 CD8+ AIM responses to XBB.1.5 were detected in only four of 10 patients after three doses.
321 CD4+ CD134+/CD69+ AIM responses to XBB.1.5 were significantly weaker than responses to
322 ancestral SARS-CoV-2 at pre-second dose (5.0-fold lower, $p = 0.0078$) and post-third dose

323 timepoints (2.0-fold lower, $p = 0.0020$) (**Figure 6B**). CD8⁺ CD137⁺/CD69⁺ AIM responses to
324 XBB.1.5 clearly trended lower (4.8-fold lower, $p = 0.0781$) at the pre-second dose timepoint,
325 with XBB.1.5 responses detectable in only two of ten patients (seven of ten patients responded to
326 the ancestral protein), and were significantly weaker than ancestral SARS-CoV-2 responses after
327 three doses (18-fold lower, $p = 0.0156$) (**Figure 6B**).

328 **Discussion**

329 As SARS-CoV-2 variants continue to evolve, understanding vaccine immunogenicity in
330 vulnerable populations is critical to informing vaccination strategies. SOTRs show impaired
331 humoral and cellular responses to mRNA vaccines^{5,9,28,30}, corresponding with increased
332 susceptibility to infection^{4,25}. In the present study, we have provided the first AIM based-
333 characterization of COVID-19 vaccine-induced T cell responses in SOTRs. We demonstrate
334 significant T cell responses to vaccination which persist over time and are enhanced by booster
335 doses. Although monovalent vaccination with the ancestral strain induced T cells capable of
336 cross-recognizing BA.4/5 and XBB.1.5, responses to these variants were weaker than those to
337 the ancestral strain.

338 We observed strong induction of SARS-CoV-2-specific AIM responses to both ancestral SARS-
339 CoV-2 and BA.4/5 by second and third doses of mRNA vaccine, particularly among CD4⁺ T
340 cells. Although responses trended lower over time at the six-month and one-year timepoints,
341 CD4⁺ T cell responses remained significantly elevated above pre-second dose levels and were
342 further enhanced by a fourth dose. Our data confirm studies showing that SOTRs mount
343 significant T cell responses to mRNA vaccination^{9,25,28,29,31}, and represent the first AIM-based
344 characterization of BA.4/5-cross-reactive T cells in SOTRs. We show that even two-dose mRNA
345 vaccination significantly induces BA.4/5 cross-reactivity, however, this declines over time and at
346 least one additional (i.e. third) dose may be required to achieve lasting BA.4/5-specific T cell
347 memory. Indeed, longitudinal analyses of immune-suppressed patients with diverse pathologies
348 observe sharp declines in post-second dose responses^{28,50}, while responses remain stable at
349 similar magnitudes to healthy individuals following third and fourth doses⁵⁰. Interestingly,
350 breakthrough infection did not appear to further enhance BA.4/5-specific responses in patients
351 who received a fourth dose, despite cases occurring during a global Omicron wave. Of note,
352 these infections occurred more than four months (IQR 111-148 days) prior to one-year sampling,
353 thus the acute T cell response to infection was likely not captured.

354 We also established clinical factors associated with BA.4/5-specific T cell responses to
355 vaccination. Although responses in patients taking prednisone were decreased, consistent with
356 studies of BA.4/5 neutralization in SOTRs⁹, all lung recipients in our cohort, and no liver
357 recipients, were receiving prednisone in accordance with regional guidelines⁵¹. When analyzing
358 differences between organ groups, lung recipients responded weakly compared to liver and
359 kidney recipients. This is likely due to the more intense immunosuppression given to lung
360 transplant recipients^{52,53}. Others have demonstrated impaired vaccine-induced IFN- γ responses
361 and increased COVID-19 mortality in lung recipients^{5,54,55}. We also demonstrate a negative
362 relationship between age and BA.4/5-specific AIM responses. CD8⁺ AIM responses showed

363 particularly strong declines with increasing patient age, congruent with greater susceptibility to
364 ageing in CD8+ T cells than CD4+ T cells⁵⁶⁻⁵⁸.

365 As CD4+ T cells promote high-affinity humoral responses and B cell memory⁵⁹, we analyzed
366 correlations of BA.4/5-specific AIM responses with anti-RBD and nAb titres⁹. Correlations
367 between CD4+ AIM responses and anti-RBD titres were non-significant prior to a second dose,
368 but increased in strength and significance with subsequent vaccinations, and over time even
369 without additional vaccinations. At the six-month timepoint or after three doses, patients who
370 developed antibody responses generally showed strong CD4+ AIM responses, suggesting that a
371 third dose is necessary to optimally stimulate both immune compartments and that the
372 relationship between cellular and humoral immunity may also strengthen with time. However, a
373 substantial number of patients with no detectable anti-RBD titres after two or three doses showed
374 strong AIM responses, hinting that T cells could play a critical protective role in these antibody-
375 deficient SOTRs^{21,60}. Furthermore, post-second dose T cell responses strongly predicted post-
376 third dose antibody responses, supporting a causative relationship between antigen-specific
377 CD4+ T cells and humoral responses. We also observed trending associations between BA.4/5-
378 specific AIM responses and BA.4/5-nAbs, but these were non-significant as few patients
379 developed post-third dose BA.4/5-nAbs.

380 The BA.4/5 and XBB.1.5 variants escape antibody-mediated neutralization in individuals
381 vaccinated against the ancestral strain^{13,16-20,61}. CD4+ and CD8+ T cell responses have thus far
382 shown conserved cross-reactivity with Omicron^{18,26,27,62} including BA.4/5 in immune-
383 compromised patients and SOTRs^{31,63}, but no data existed for T cell responses to XBB.1.5. In
384 contrast to previous research, we found significant decreases in T cell recognition of BA.4/5
385 relative to the ancestral strain. We are the first to investigate BA.4/5 cross-recognition in SOTRs
386 using an AIM assay, which detects cytokine-negative T cells and rare populations with higher
387 sensitivity than ICS^{33,34}, lending itself well to detecting small differences. We obtained similar
388 results for XBB.1.5, showing strongly impaired T cell cross-recognition in monovalent ancestral-
389 vaccinated SOTRs. However, despite their lower magnitude, CD4+ responses to BA.4/5 and
390 XBB.1.5 were induced by vaccination, consistent with broad epitope specificity of CD4+ T
391 cells⁶⁴, and displayed similar kinetics to ancestral responses. Thus, impairments in T cell cross-
392 recognition may not severely impact vaccine immunogenicity for these variants. Large-scale
393 epidemiological data in SOTRs show significantly decreased incidence of hospitalization and
394 death following the emergence of Omicron, suggesting adequate vaccine-mediated protection
395 from severe outcomes in this highly transmissible but low-virulence variant⁴. The full impact of
396 the recent wave of XBB.1.5 infections on SOTRs remains to be seen.

397 Our study entails several inherent limitations. First, we are unable to draw conclusions regarding
398 the magnitude of AIM responses in SOTRs relative to the general population as we did not
399 include healthy controls in the study. This also precludes the extension of novel findings, such as
400 impaired T cell responses to BA.4/5 and XBB.1.5, beyond the SOTR population. Second, our
401 sample size was insufficient to adequately assess effects of certain clinical parameters such as
402 antimetabolite or tacrolimus use, or whether AIM responses predict subsequent infection or
403 hospitalization. Finally, our method provided more robust characterization of CD4+ T cell

404 responses than CD8⁺ T cell responses. This may be a feature of the peptide mixes used, which
405 consist of 15-mers. CD4⁺ T cells recognize peptides from 11-20 amino acids, while CD8⁺ T
406 cells optimally recognize peptides of 8-11 amino acids⁶⁵. However, CD8⁺ T cell responses were
407 also poorly detected using whole protein stimulation (**Figure 6**), and others have observed lower
408 magnitudes of Spike-specific CD8⁺ responses using diverse methods^{43,44,60,66,67}. Thus, CD8⁺ T
409 cells may preferentially respond to non-Spike antigens, including internal viral proteins⁴⁴, and
410 Spike-based assays may not capture the full complement of SARS-CoV-2-specific CD8⁺ T cells.

411 Overall, we demonstrate that SOTRs mount significant BA.4/5-cross-reactive T cell responses to
412 ancestral COVID-19 mRNA vaccines, with booster doses enhancing responses. However, using
413 a sensitive AIM assay, we show that cross-recognition of BA.4/5 and XBB.1.5 is significantly
414 impaired in SOTRs. We also demonstrate strong correlations between CD4⁺ T cell responses and
415 antibody responses, and identify weaker cellular responses in older adults and lung recipients
416 receiving prednisone. Our data provide unique insights into the kinetics of variant-specific T cell
417 responses in immune-compromised patients, with important implications for clinical and public
418 health guidelines.

419 **Acknowledgements**

420 We wish to express our deepest gratitude to those who participated in this study. Finally, we wish
421 to thank Lisa Xu at the BC Children's Hospital Research Institute Flow Cytometry Core for her
422 invaluable assistance with data acquisition. The study was coordinated by the Canadian Donation
423 and Transplantation Research Program.

424 **PREVenT COVID group investigators:** PREVenT COVID group investigators: Jean-Sébastien
425 Delisle (Hôpital Maisonneuve Rosemont (HMR), Sasan Hosseini-Moghaddam (University
426 Health Network (UHN)), Dr. Héloïse Cardinal (Centre hospitalier de l'Université de Montréal
427 (CHUM)), Dr. Mélanie Dieudé (Centre hospitalier de l'Université de Montréal (CHUM)), Dr.
428 Normand Racine (Institut de Cardiologie de Montréal (ICM)), Dr. Karina Top (Dalhousie
429 University), Dr. Gaston DeSerres (INSPQ, Public Health), Dr. Lori West (University of Alberta
430 (UofA), CDTRP)), Dr. Marc Cloutier (HémaQuébec), Dr. Renée Bazin (Héma-Québec), Dr.
431 Christopher Lemieux (Université Laval), Dr. Sacha De Serres (Université Laval), Dr. Atul
432 Humar (University Health Network (UHN)), Dr. Sarah Shalhoub (London Health Sciences
433 Center (LHSC)), Dr. Dima Kabbani (University of Alberta (UofA)), Dr. Marie-Josée Hébert
434 (Centre hospitalier de l'Université de Montréal (CHUM)), Dr. Patricia Gongal (CDTRP),
435 Kristian Stephens (CDTRP).

436 **PREVenT COVID Group Coordinators:** Dr. Julie Turgeon (CHUM), Zineb Khrifi (CHUM),
437 France Samson (Université Laval), Maryse Desjardins (ICM), Hélène Brown (ICM), Johanne
438 Doiron (ICM), Cadence Baker (London Health Sciences Centre, LHSC), Taylor Toth (LHSC),
439 Grant Luke (LHSC), Natalia Pinzon (UHN), Victoria G. Hall (UHN), Kimberly Robertson
440 (UofA), Heather Mangan (UofA).

441

442

443 References

- 444 1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-
445 CoV-2 Vaccine. *N Engl J Med*. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
- 446 2. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against
447 SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-
448 regression. *Lancet*. 2022;399(10328):924-944. doi:10.1016/S0140-6736(22)00152-0
- 449 3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-
450 19 Vaccine. *N Engl J Med*. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
- 451 4. Overvad M, Koch A, Jespersen B, et al. Outcomes following SARS-CoV-2 infection in
452 individuals with and without solid organ transplantation—A Danish nationwide cohort study.
453 *Am J Transplant*. 2022;22(11):2627-2636. doi:10.1111/ajt.17142
- 454 5. Hamm SR, Møller DL, Pérez-Alós L, et al. Decline in Antibody Concentration 6 Months
455 After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients
456 and Healthy Controls. *Front Immunol*. 2022;13. Accessed April 20, 2023.
457 <https://www.frontiersin.org/articles/10.3389/fimmu.2022.832501>
- 458 6. Chang CC, Vlad G, Vasilescu ER, et al. Previous SARS-CoV-2 infection or a third dose of
459 vaccine elicited cross-variant neutralising antibodies in vaccinated solid-organ transplant
460 recipients. *Clin Transl Immunol*. 2022;11(8):e1411. doi:10.1002/cti2.1411
- 461 7. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2
462 mRNA Vaccine Series in Solid Organ Transplant Recipients. *JAMA*. 2021;325(21):2204-
463 2206. doi:10.1001/jama.2021.7489
- 464 8. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a Single Dose of SARS-CoV-
465 2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. *JAMA*.
466 2021;325(17):1784-1786. doi:10.1001/jama.2021.4385
- 467 9. Ferreira VH, Ierullo M, Mavandadnejad F, et al. Omicron BA.4/5 neutralization and T-cell
468 responses in organ transplant recipients after Booster mRNA vaccine: a Multicenter Cohort
469 Study. *Clin Infect Dis Off Publ Infect Dis Soc Am*. Published online March 28, 2023:ciad175.
470 doi:10.1093/cid/ciad175
- 471 10. Karaba AH, Johnston TS, Aytenfisu TY, et al. A Fourth Dose of COVID-19 Vaccine Does
472 Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients
473 With Suboptimal Vaccine Response. *Transplantation*. 2022;106(7):1440.
474 doi:10.1097/TP.0000000000004140
- 475 11. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron
476 (B.1.1.529) Variant. *N Engl J Med*. 2022;386(16):1532-1546. doi:10.1056/NEJMoa2119451
- 477 12. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation
478 and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants

- 479 in England: a cohort study. *Lancet*. 2022;399(10332):1303-1312. doi:10.1016/S0140-
480 6736(22)00462-7
- 481 13. Tuekprakhon A, Nutalai R, Djokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2
482 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. *Cell*. 2022;185(14):2422-2433.e13.
483 doi:10.1016/j.cell.2022.06.005
- 484 14. Uriu K, Ito J, Zahradnik J, et al. Enhanced transmissibility, infectivity, and immune
485 resistance of the SARS-CoV-2 omicron XBB.1.5 variant. *Lancet Infect Dis*. 2023;23(3):280-
486 281. doi:10.1016/S1473-3099(23)00051-8
- 487 15. Yue C, Song W, Wang L, et al. ACE2 binding and antibody evasion in enhanced
488 transmissibility of XBB.1.5. *Lancet Infect Dis*. 2023;23(3):278-280. doi:10.1016/S1473-
489 3099(23)00010-5
- 490 16. Bowen JE, Addetia A, Dang HV, et al. Omicron spike function and neutralizing activity
491 elicited by a comprehensive panel of vaccines. *Science*. 2022;377(6608):890-894.
492 doi:10.1126/science.abq0203
- 493 17. Djokaite-Guraliuc A, Das R, Zhou D, et al. Rapid escape of new SARS-CoV-2 Omicron
494 variants from BA.2-directed antibody responses. *Cell Rep*. 2023;42(4).
495 doi:10.1016/j.celrep.2023.112271
- 496 18. Muik A, Lui BG, Quandt J, et al. Progressive loss of conserved spike protein neutralizing
497 antibody sites in Omicron sublineages is balanced by preserved T cell immunity. *Cell Rep*.
498 2023;42(8). doi:10.1016/j.celrep.2023.112888
- 499 19. Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2,
500 BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. *Nat Med*.
501 2023;29(2):344-347. doi:10.1038/s41591-022-02162-x
- 502 20. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2
503 BQ and XBB subvariants. *Cell*. 2023;186(2):279-286.e8. doi:10.1016/j.cell.2022.12.018
- 504 21. Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2
505 infection and COVID-19 disease. *Immunol Rev*. 2022;310(1):6-26. doi:10.1111/imr.13091
- 506 22. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*.
507 2021;184(4):861-880. doi:10.1016/j.cell.2021.01.007
- 508 23. Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19
509 vaccines. *Immunol Rev*. 2022;310(1):27-46. doi:10.1111/imr.13089
- 510 24. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive Immunity
511 to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*.
512 2020;183(4):996-1012.e19. doi:10.1016/j.cell.2020.09.038

- 513 25. Barnes E, Goodyear CS, Willicombe M, et al. SARS-CoV-2-specific immune responses and
514 clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.
515 *Nat Med.* 2023;29(7):1760-1774. doi:10.1038/s41591-023-02414-4
- 516 26. Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the
517 Omicron variant. *Nat Med.* 2022;28(3):472-476. doi:10.1038/s41591-022-01700-x
- 518 27. Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell
519 memory able to cross-recognize variants from Alpha to Omicron. *Cell.* 2022;185(5):847-
520 859.e11. doi:10.1016/j.cell.2022.01.015
- 521 28. Gao Y, Cai C, Wullimann D, et al. Immunodeficiency syndromes differentially impact the
522 functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. *Immunity.*
523 2022;55(9):1732-1746.e5. doi:10.1016/j.immuni.2022.07.005
- 524 29. Ferreira VH, Marinelli T, Ierullo M, et al. Severe Acute Respiratory Syndrome Coronavirus 2
525 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ
526 Transplant Recipients. *J Infect Dis.* 2021;224(11):1849-1860. doi:10.1093/infdis/jiab542
- 527 30. Reza Hosseini O, Hamm SR, Heftdal LD, et al. Humoral and T-cell response 12 months after
528 the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics,
529 associated factors, and role of SARS-CoV-2 infection. *Front Immunol.* 2023;13. Accessed
530 April 24, 2023. <https://www.frontiersin.org/articles/10.3389/fimmu.2022.1075423>
- 531 31. Thompson EA, Ngecu W, Stoddart L, et al. Heterologous versus homologous boosting elicits
532 qualitatively distinct, BA.5-cross-reactive T cells in transplant recipients. *JCI Insight.*
533 2023;8(10). doi:10.1172/jci.insight.168470
- 534 32. Altosole T, Rotta G, Uras CRM, Bornheimer SJ, Fenoglio D. An optimized flow cytometry
535 protocol for simultaneous detection of T cell activation induced markers and intracellular
536 cytokines: Application to SARS-CoV-2 immune individuals. *J Immunol Methods.*
537 2023;515:113443. doi:10.1016/j.jim.2023.113443
- 538 33. Poloni C, Schonhofer C, Ivison S, Levings MK, Steiner TS, Cook L. T-cell activation-
539 induced marker assays in health and disease. *Immunol Cell Biol.* Published online February
540 24, 2023. doi:10.1111/imcb.12636
- 541 34. Bacher P, Scheffold A. Flow-cytometric analysis of rare antigen-specific T cells. *Cytometry*
542 *A.* 2013;83A(8):692-701. doi:10.1002/cyto.a.22317
- 543 35. Elias G, Ogunjimi B, Van Tendeloo V. Activation-induced surface proteins in the
544 identification of antigen-responsive CD4 T cells. *Immunol Lett.* 2020;219:1-7.
545 doi:10.1016/j.imlet.2019.12.006
- 546 36. Braun J, Loyal L, Frensch M, et al. SARS-CoV-2-reactive T cells in healthy donors and
547 patients with COVID-19. *Nature.* 2020;587(7833):270-274. doi:10.1038/s41586-020-2598-9

- 548 37. Kabbani D, Yotis DM, Ferreira VH, et al. Immunogenicity, Safety, and Breakthrough Severe
549 Acute Respiratory Syndrome Coronavirus 2 Infections After Coronavirus Disease 2019
550 Vaccination in Organ Transplant Recipients: A Prospective Multicenter Canadian Study.
551 *Open Forum Infect Dis.* 2023;10(5):ofad200. doi:10.1093/ofid/ofad200
- 552 38. Reiss S, Baxter AE, Cirelli KM, et al. Comparative analysis of activation induced marker
553 (AIM) assays for sensitive identification of antigen-specific CD4 T cells. *PLOS ONE.*
554 2017;12(10):e0186998. doi:10.1371/journal.pone.0186998
- 555 39. Dan JM, Lindestam Arlehamn CS, Weiskopf D, et al. A Cytokine-Independent Approach To
556 Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare
557 Antigen-Specific CD4+ T Cells in Blood. *J Immunol Baltim Md 1950.* 2016;197(3):983-993.
558 doi:10.4049/jimmunol.1600318
- 559 40. Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection,
560 isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without
561 requiring knowledge of epitope specificities. *Blood.* 2007;110(1):201-210.
562 doi:10.1182/blood-2006-11-056168
- 563 41. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-
564 specific CD8+ T cells by a flow cytometric assay for degranulation. *J Immunol Methods.*
565 2003;281(1):65-78. doi:10.1016/S0022-1759(03)00265-5
- 566 42. Bowyer G, Rampling T, Powlson J, et al. Activation-induced Markers Detect Vaccine-
567 Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical
568 Trials. *Vaccines.* 2018;6(3):50. doi:10.3390/vaccines6030050
- 569 43. Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+ T cells induced
570 by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nat Immunol.*
571 2020;21(11):1336-1345. doi:10.1038/s41590-020-0782-6
- 572 44. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2
573 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell.*
574 2020;181(7):1489-1501.e15. doi:10.1016/j.cell.2020.05.015
- 575 45. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to
576 8 months after infection. *Science.* 2021;371(6529):eabf4063. doi:10.1126/science.abf4063
- 577 46. Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen-specific CD4+ T cells is
578 associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA
579 vaccination. *Immunity.* 2021;54(9):2133-2142.e3. doi:10.1016/j.immuni.2021.08.001
- 580 47. Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and
581 CD8+ T cell reactivity in infected or vaccinated individuals. *Cell Rep Med.*
582 2021;2(7):100355. doi:10.1016/j.xcrm.2021.100355
- 583 48. Paul K, Sibbertsen F, Weiskopf D, et al. Specific CD4+ T Cell Responses to Ancestral
584 SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant.

- 585 *Front Immunol.* 2022;13. Accessed August 2, 2023.
586 <https://www.frontiersin.org/articles/10.3389/fimmu.2022.867577>
- 587 49. Newell KL, Waldran MJ, Thomas SJ, Endy TP, Waickman AT. Simultaneous analysis of
588 antigen-specific B and T cells after SARS-CoV-2 infection and vaccination. *Cytometry.*
589 2022;101(6):474-482. doi:10.1002/cyto.a.24563
- 590 50. Cheung MW, Dayam RM, Shapiro JR, et al. Third and Fourth Vaccine Doses Broaden and
591 Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory
592 Diseases. *J Immunol.* Published online June 16, 2023:ji2300190.
593 doi:10.4049/jimmunol.2300190
- 594 51. BC Transplant, Provincial Health Services Authority. Medication Guidelines for Solid Organ
595 Transplants. Published online May 13, 2021. Accessed July 9, 2023.
596 [http://www.transplant.bc.ca/health-professionals/transplant-resources/transplant-clinical-](http://www.transplant.bc.ca/health-professionals/transplant-resources/transplant-clinical-guidelines/medication-guidelines)
597 [guidelines/medication-guidelines](http://www.transplant.bc.ca/health-professionals/transplant-resources/transplant-clinical-guidelines/medication-guidelines)
- 598 52. Korom S, Boehler A, Weder W. Immunosuppressive therapy in lung transplantation: state of
599 the art☆. *Eur J Cardiothorac Surg.* 2009;35(6):1045-1055. doi:10.1016/j.ejcts.2009.02.035
- 600 53. Ng CY, Madsen JC, Rosengard BR, Allan JS. Immunosuppression for lung transplantation.
601 *Front Biosci J Virtual Libr.* 2009;14:1627-1641.
- 602 54. Meshram HS, Kute V, Rane H, et al. Humoral and cellular response of COVID-19 vaccine
603 among solid organ transplant recipients: A systematic review and meta-analysis. *Transpl*
604 *Infect Dis.* Published online August 12, 2022:e13926. doi:10.1111/tid.13926
- 605 55. Schaenman J, Byford H, Grogan T, et al. Impact of solid organ transplant status on outcomes
606 of hospitalized patients with COVID-19 infection. *Transpl Infect Dis.* 2022;24(4):e13853.
607 doi:10.1111/tid.13853
- 608 56. Czesnikiewicz-Guzik M, Lee WW, Cui D, et al. T cell subset-specific susceptibility to aging.
609 *Clin Immunol Orlando Fla.* 2008;127(1):107-118. doi:10.1016/j.clim.2007.12.002
- 610 57. Moro-García MA, Alonso-Arias R, López-Larrea C. When Aging Reaches CD4+ T-Cells:
611 Phenotypic and Functional Changes. *Front Immunol.* 2013;4:107.
612 doi:10.3389/fimmu.2013.00107
- 613 58. Weinberger B, Lazuardi L, Weiskirchner I, et al. Healthy aging and latent infection with
614 CMV lead to distinct changes in CD8+ and CD4+ T-cell subsets in the elderly. *Hum*
615 *Immunol.* 2007;68(2):86-90. doi:10.1016/j.humimm.2006.10.019
- 616 59. Elgueta R, Benson MJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism
617 and function of CD40/CD40L engagement in the immune system. *Immunol Rev.*
618 2009;229(1):152-172. doi:10.1111/j.1600-065X.2009.00782.x
- 619 60. Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol.* 2022;23(2):186-
620 193. doi:10.1038/s41590-021-01122-w

- 621 61. Jeong HW, Kim SM, Jung MK, et al. Enhanced antibody responses in fully vaccinated
622 individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
623 *Cell Rep Med*. 2022;3(10). doi:10.1016/j.xcrm.2022.100764
- 624 62. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-
625 recognize Omicron. *Nature*. 2022;603(7901):488-492. doi:10.1038/s41586-022-04460-3
- 626 63. Qui M, Bert NL, Chan WPW, et al. Favorable vaccine-induced SARS-CoV-2-specific T cell
627 response profile in patients undergoing immune-modifying therapies. *J Clin Invest*.
628 2022;132(12). doi:10.1172/JCI159500
- 629 64. Tye EXC, Jinks E, Haigh TA, et al. Mutations in SARS-CoV-2 spike protein impair epitope-
630 specific CD4+ T cell recognition. *Nat Immunol*. 2022;23(12):1726-1734.
631 doi:10.1038/s41590-022-01351-7
- 632 65. Rosa DS, Ribeiro SP, Cunha-Neto E. CD4+ T Cell Epitope Discovery and Rational Vaccine
633 Design. *Arch Immunol Ther Exp (Warsz)*. 2010;58(2):121-130. doi:10.1007/s00005-010-
634 0067-0
- 635 66. Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and broad
636 immune memory after SARS-CoV-2 infection with persisting antibody responses and
637 memory B and T cells. *Cell Rep Med*. 2021;2(7). doi:10.1016/j.xcrm.2021.100354
- 638 67. Ogbe A, Kronsteiner B, Skelly DT, et al. T cell assays differentiate clinical and subclinical
639 SARS-CoV-2 infections from cross-reactive antiviral responses. *Nat Commun*.
640 2021;12(1):2055. doi:10.1038/s41467-021-21856-3

641

642

643

644

645

646

647

648

649

650

651

652

653 **Table 1. Study Cohort Characteristics**

Characteristic	n (%) or median [IQR] ^a			Total
	Kidney	Liver	Lung	
<i>Sample size</i>	16	16	10	42
Pre-2nd dose	5 (31%)	12 (75%)	4 (40%)	21 (50%)
Post-2nd dose	16 (100%)	16 (100%)	8 (80%)	40 (95%)
Six months post-1st dose	3 (19%)	4 (25%)	4 (40%)	11 (26%)
Post-3rd dose	14 (88%)	11 (69%)	8 (80%)	33 (79%)
One year post-1st dose	14 (88%)	9 (56%)	9 (90%)	32 (76%)
Neither 4th dose nor COVID-19	1 (6%)	4 (25%)	1 (10%)	6 (14%)
Post-4th dose (no COVID-19)	7 (44%)	4 (25%)	4 (40%)	15 (36%)
Hybrid (4th dose + COVID-19)	6 (38%)	1 (6%)	0 (0%)	7 (17%)
COVID-19 (no 4th dose)	0 (0%)	0 (0%)	4 (40%)	4 (10%)
<i>Sample collection timing</i>				
1st dose to pre-2nd dose sample (days)	73 [40, 84]	71 [47, 76]	70 [69, 75]	70 [53, 79]
2nd dose to post-2nd dose sample (days)	29 [26, 33]	29 [28, 33]	34 [29, 35]	29 [26, 34]
2nd dose to 6 month sample (days)	105	146 [128, 152]	105 [102, 108]	109 [100, 134]
3rd dose to post-3rd dose sample (days)	33 [28, 40]	31 [29, 36]	32 [28, 36]	32 [28, 39]
3rd dose to 1 year sample (no 4th dose or COVID-19) (days)	232	203 [194, 209]	217	211 [200, 216]
4th dose to 1 year sample (no COVID-19) (days)	28 [27, 39]	22 [20, 27]	30 [25, 35]	27 [22, 39]
4th dose to 1 year sample (hybrid) (days)	34 [26, 39]	36		35 [28, 38]
COVID-19 to 1 year sample (hybrid) (days)	135 [110, 151]	118		126 [111, 148]
<i>Age</i>	55 [46, 66]	62 [50, 66]	56 [49, 65]	58 [47, 66]
<i>Time since transplant (y)</i>	4.6 [2.8, 8.0]	8.7 [4.5, 13.9]	9.0 [4.3, 14.1]	6.8 [3.2, 12.9]
<i>Sex</i>				
Female	8 (50%)	9 (56%)	5 (50%)	22 (52%)
Male	8 (50%)	7 (44%)	5 (50%)	20 (48%)
<i>Vaccinations</i>				
1st dose	16 (100%)	16 (100%)	10 (100%)	42 (100%)
Moderna	2 (13%)	6 (38%)	0 (0%)	8 (19%)
Pfizer-BioNTech	14 (88%)	10 (63%)	10 (100%)	34 (81%)

2nd dose	16 (100%)	16 (100%)	10 (100%)	42 (100%)
Moderna	2 (13%)	8 (50%)	0 (0%)	10 (24%)
Pfizer-BioNTech	14 (88%)	8 (50%)	10 (100%)	32 (76%)
3rd dose	15 (94%)	13 (81%)	10 (100%)	38 (90%)
Moderna	6 (38%)	11 (69%)	6 (60%)	23 (55%)
Pfizer-BioNTech	9 (56%)	2 (13%)	4 (40%)	15 (36%)
4th dose	14 (88%)	12 (75%)	9 (90%)	35 (83%)
Moderna	11 (69%)	11 (69%)	7 (70%)	29 (69%)
Pfizer-BioNTech	3 (19%)	1 (6%)	2 (20%)	6 (14%)
<i>Immunosuppression at enrollment</i>				
Prednisone	10 (63%)	0 (0%)	10 (100%)	20 (48%)
Cyclosporine	0 (0%)	1 (6%)	0 (0%)	1 (2%)
Tacrolimus	16 (69%)	11 (69%)	10 (100%)	35 (83%)
Mycophenolate mofetil or mycophenolate sodium	12 (44%)	7 (44%)	8 (80%)	27 (64%)
Azathioprine	3 (19%)	1 (6%)	1 (10%)	5 (12%)
Sirolimus	0 (0%)	3 (19%)	0 (0%)	3 (7%)

654 ^aOnly medians are reported when groups have fewer than n = 4

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671 **Table 2. Correlations of anti-RBD titres with T cell activation-induced marker responses**

Timepoint	Variant	Spearman's r	P-value	Significance
<i>CD4+ T cells (CD134+/CD69+)</i>				
pre-2nd	Ancestral	0.2369	0.2884	ns
pre-2nd	BA.4/5	0.4066	0.0604	ns
post-2nd	Ancestral	0.3064	0.0514	ns
post-2nd	BA.4/5	0.3091	0.0493	*
6 months	Ancestral	0.8028	0.0082	**
6 months	BA.4/5	0.6554	0.0454	*
post-3rd	Ancestral	0.6755	<0.0001	****
post-3rd	BA.4/5	0.6411	<0.0001	****
<i>CD8+ T cells (CD137+/CD69+)</i>				
pre-2nd	Ancestral	0.4273	0.0534	ns
pre-2nd	BA.4/5	0.3288	0.1456	ns
post-2nd	Ancestral	0.2832	0.0727	ns
post-2nd	BA.4/5	0.2726	0.0847	ns
6 months	Ancestral	0.6457	0.0512	ns
6 months	BA.4/5	0.6241	0.0591	ns
post-3rd	Ancestral	0.3527	0.0441	*
post-3rd	BA.4/5	0.3313	0.0596	ns

672

673 ns, non-significant; *p <0.05, **p <0.01; ***p <0.001; ****p <0.0001

674

675

676

677

678

679

680

681

682


683

684


685

Figure 1


A



B



C



687 **Figure 1. Second and third vaccine doses induce durable Omicron BA.4/5-specific T cell**
688 **responses in solid-organ transplant recipients. A)** PBMC samples from solid organ transplant
689 recipients (SOTRs, n = 42) immunized with COVID-19 mRNA vaccines were collected at pre-
690 second dose, post-second dose, six months post-first dose, post-third dose and one-year
691 timepoints. **B)** Representative flow cytometry data showing T cell activation-induced marker
692 (AIM) responses to the ancestral strain of SARS-CoV-2 in one donor after three doses of a
693 COVID-19 mRNA vaccine. Samples were stimulated with 1 µg/mL SARS-CoV-2 ancestral
694 strain or Omicron BA.4/5 Spike peptides for 20 h. CD4+ T cell activation-induced marker (AIM)
695 responses were measured as frequencies of CD134+/CD25+, CD134+/CD69+ or
696 CD137+/CD69+ events among CD4+ T cells. CD8+ AIM responses were measured as
697 frequencies of CD107a+/CD69+, CD107a+/CD137+ or CD137+/CD69+ events among CD8+ T
698 cells. All data represent net AIM+ frequencies after subtracting the equivalent AIM+ frequency
699 in the DMSO-stimulated control. **C)** Time course of CD4+ and CD8+ T cell AIM responses to
700 ancestral SARS-CoV-2 and BA.4/5 in SOTRs. Participants who had already received a third dose
701 were excluded at the six-month timepoint, and participants who received a fourth dose or
702 developed COVID-19 were excluded at the one-year timepoint to model the natural history of
703 the vaccine-induced T cell response. P-values represent Dunnett's multiple comparisons test
704 following a mixed effects analysis on log₂-transformed AIM+ frequencies.

705

706

707

708

709

710

711

712

713

714

715

716


717

718

719

720

Figure 2



721

722

723

724

725

726 **Figure 2. A fourth vaccine dose enhances SARS-CoV-2-specific T cell responses in solid**
727 **organ transplant recipients.** PBMCs from solid organ transplant recipients (SOTRs) were
728 collected at post-third dose and one year post-first dose (6-8 months post-third dose) timepoints
729 and stimulated with 1 µg/mL SARS-CoV-2 ancestral strain or Omicron BA.4/5 Spike peptides
730 for 20 h. T cell activation-induced marker (AIM) responses were quantified as CD134+/CD69+
731 or CD137+/CD69+ frequencies among CD4+ and CD8+ T cells, respectively, after subtraction of
732 the equivalent AIM+ frequency in the DMSO-stimulated control. **A)** At the one-year timepoint,
733 SOTRs were grouped as having received neither a fourth dose nor a contracting COVID-19
734 (controls, n = 6), having received a fourth monovalent COVID-19 mRNA vaccine dose within 3-
735 6 weeks of sample collection (fourth dose, n = 15), or a fourth dose and symptomatic COVID-19
736 (hybrid, n = 7). Patients who had only COVID-19 infection (n = 4) were excluded due to
737 insufficient sample size. **B)** Evolution of CD4+ and CD8+ T cell AIM responses in from the
738 post-third dose to one-year timepoint within fourth dose, hybrid and control groups of SOTRs.
739 Paired Wilcoxon signed-rank test p-values are shown. **C)** Effect of a fourth dose or hybrid
740 immunity on CD4+ and CD8+ T cell AIM responses in SOTRs. Changes from post-third dose to
741 one-year timepoints are compared between fourth dose, hybrid and control groups. P-values
742 represent Dunn's multiple comparisons test following a Kruskal-Wallis test.

743

744


745

746

747

748

Figure 3



749

750

751 **Figure 3. T cell activation-induced marker responses to Omicron BA.4/5 are weaker than**
752 **responses to ancestral SARS-CoV-2 in solid organ transplant recipients.** Paired comparisons
753 of CD4+ (A) and CD8+ (B) T cell AIM responses to Omicron BA.4/5 and ancestral SARS-CoV-
754 2, measured after three doses of a COVID-19 mRNA vaccine, in solid organ transplant recipients
755 (n = 33). Following a 20-h stimulation of patient PBMCs with 1 μ g/mL SARS-CoV-2 ancestral
756 strain or Omicron BA.4/5 Spike peptides, CD4+ T cell activation-induced marker (AIM)
757 responses were quantified as frequencies of CD134+/CD25+, CD134+/CD69+ or
758 CD137+/CD69+ events among CD4+ T cells, while CD8+ AIM responses were measured as
759 frequencies of CD107a+/CD69+, CD107a+/CD137+ or CD137+/CD69+ events among CD8+ T
760 cells, after subtracting the equivalent AIM+ frequency in the DMSO-stimulated control.
761 Wilcoxon signed-rank test p-values are shown.

762

763

764


765

766


767

Figure 4


A



B



C



769 **Figure 4. Prednisone, lung transplantation and older age are associated with weaker T cell**
770 **responses to COVID-19 vaccination.** Post-third dose CD4+ and CD8+ T cell activation-
771 induced marker (AIM) responses to SARS-CoV-2 ancestral and Omicron BA.4/5 variants are
772 shown in solid-organ transplant recipients. Patient PBMCs were stimulated for 20 h with 1
773 $\mu\text{g}/\text{mL}$ SARS-CoV-2 ancestral strain or Omicron BA.4/5 Spike peptides, and T cell activation-
774 induced marker responses were quantified by flow cytometry as frequencies of CD134+/CD69+
775 events among CD4+ T cells, or CD137+/CD69+ events among CD8+ T cells, after subtracting
776 the equivalent AIM+ frequency in the DMSO-stimulated control. **A)** Mann-Whitney U-test
777 comparing AIM responses between patients receiving baseline prednisone ($n = 17$) and those not
778 receiving prednisone ($n = 16$). Symbols differentiate between kidney (black circles), liver (red
779 squares) and lung (blue triangles) transplant recipients. **B)** Comparisons of AIM responses
780 between kidney ($n = 14$), liver ($n = 11$) and lung ($n = 8$) transplant recipients. Dunn's multiple
781 comparisons p-values are shown following a Kruskal-Wallis test. **C)** Semilogarithmic regression
782 analysis of the relationship between age and T cell AIM responses, testing the null hypothesis of
783 the slope being equal to zero.

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798


799

800


801

Figure 5


A



B



C



803 **Figure 5. SARS-CoV-2-specific T cell activation-induced marker responses correlate with**
804 **Spike-specific antibody titres in solid organ transplant recipients.** Relationships of T cell
805 activation-induced marker (AIM) responses with previously published anti-Spike binding and
806 neutralizing antibodies are shown in solid organ transplant recipients⁹. PBMCs were collected
807 from COVID-19-vaccinated SOTRs at pre-second dose, post-second dose, six months post-first
808 dose and post-fourth dose timepoints. AIM responses are shown as frequencies of
809 CD134+/CD69+ or CD137+/CD69+ events among CD4+ or CD8+ T cells, respectively,
810 following stimulation for 20 h with 1 µg/mL SARS-CoV-2 ancestral strain or Omicron BA.4/5
811 Spike peptides, after subtracting the equivalent AIM+ frequency in the DMSO-stimulated
812 control. **A)** Spearman's correlations of CD4+ and CD8+ T cell activation-induced marker
813 responses to ancestral or Omicron BA.4/5 variants of SARS-CoV-2 with circulating anti-Spike
814 antibody titres. Correlations were analyzed separately at pre-second dose (green circles, n = 21),
815 post-second dose (blue triangles, n = 40), six months post-first dose (red squares, n = 10) and
816 third dose (black triangles, n = 33) vaccination timepoints. **B)** Log-log regression analysis of
817 post-second dose CD4+ AIM responses and post-third dose anti-RBD antibody titres in SOTRs
818 who had no detectable post-second dose antibody titres, testing the null hypothesis of slope being
819 equal to zero. **C)** Comparison of post-third dose and post-fourth dose CD4+ and CD8+ T cell
820 AIM responses to BA.4/5 in patients with (nAbs) or without (no nAbs) detectable BA.4/5
821 neutralization titres. Groups were compared by unpaired two-sample t-tests on log₂-transformed
822 AIM frequencies.

823

824

825

826

827

828

829

830

831

832

833


834

835

836

837

Figure 6



839 **Figure 6. The SARS-CoV-2 variant XBB.1.5 partially escapes recognition by vaccine-**
840 **induced T cells in solid organ transplant recipients.** CD4⁺ and CD8⁺ T cell AIM responses to
841 SARS-CoV-2 ancestral strain Spike protein and XBB1.5 Spike protein, measured prior to a
842 second dose and after three doses of a COVID-19 mRNA vaccine in solid organ transplant
843 recipients (n = 10). Following a 44-h stimulation of patient PBMCs with 0.5 µg/mL SARS-CoV-
844 2 ancestral strain or XBB.1.5 Spike protein, CD4⁺ T cell activation-induced marker (AIM)
845 responses were quantified as frequencies of CD134⁺/CD69⁺ events among CD4⁺ T cells, while
846 CD8⁺ AIM responses were measured as frequencies of CD137⁺/CD69⁺ events among CD8⁺ T
847 cells, after subtraction of the equivalent AIM⁺ frequency in the PBS-stimulated control. Paired
848 Wilcoxon signed-rank test p-values are shown. **A)** Comparisons of AIM responses between pre-
849 second dose and post-third dose timepoints. **B)** Comparisons of AIM responses to ancestral
850 SARS-CoV-2 and XBB.1.5.

851